The gut microbiome is a hot emerging topic. AstraZeneca would like to take advantage of this evolving therapeutic area by partnering on innovative solutions to treat pulmonary diseases.
The gut microbiome plays an integral role in the development and homeostasis of the immune system locally and systemically. The gut-lung axis influences immunity and inflammation in the lung during health and disease.
We are seeking innovative ideas on how to modify the microbiome, or its products, specifically to treat or prevent respiratory diseases or infections causing lung inflammation. These could include, but are not limited to prebiotics and live bacterial products.